Joel Lexchin

york university - canada

H指数:49

被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The World Expected More of Canada: Canada and the Pandemic Agreement

世界对加拿大的期望更高：加拿大与《大流行病协定》

International Journal of Health Services

IF3.1

2026-06-180

PRE

New drug applications to Health Canada cancelled and refused: Cross-sectional study

加拿大卫生部新药申请的取消和拒绝：横断面研究

JRSM OPEN

IF0

2026-05-010

PRE

Are gaps in the time of submissions and approvals of new drugs between Health Canada and the Food and Drug Administration related to therapeutic value? A cross-sectional study

加拿大卫生部与食品药品监督管理局之间新药提交和审批时间间隔是否与治疗价值相关？一项横断面研究

Health Policy

IF3.4

2026-04-010

PRE

Doctors’ Conflict-of-Interest; What it Looks Like and What to do About it

医生利益冲突；它是什么样子以及如何应对

International Journal of Social Determinants of Health and Health Services

IF2.6

2026-03-190

Addressing the challenge of post-approval regulation of pharmaceuticals: The case for independent third-party evaluations

应对药品上市后监管的挑战：独立第三方评估的案例

Health Policy

IF3.4

2026-02-170

PRE

Delay in the Submission of the Results of Confirmatory Studies to Health Canada: A Cross-Sectional Study

向加拿大卫生部提交确认研究的成果存在延迟：一项横断面研究

Journal of General Internal Medicine

IF4.2

2025-11-110

PRE

Drugs Withdrawn from the Canadian Market for Safety and Effectiveness Reasons, 1990–2024: A Cross-Sectional Study

因安全性和有效性原因从加拿大市场撤回的药物，1990–2024年：一项横断面研究

Drug Safety

IF3.8

2025-09-100

PRE

Status of oncology drugs with a conditional approval: A cross-sectional comparison of the Food and Drug Administration and Health Canada

具有条件性批准的肿瘤药物现状：美国食品药品监督管理局与加拿大卫生局的横断面比较

British Journal of Clinical Pharmacology

IF3

2025-06-100

Time to completion of conditions required by Health Canada after approving new drugs: A cohort study

HEALTH POLICY

IF3.4

2025-05-010

Information About Canadian Patient Groups’ Conflicts of Interest and Industry Funding—Incomplete, Inconsistent, and Unreliable: A Cross-Sectional Study

关于加拿大患者群体利益冲突和行业资助的信息——不完整、不一致且不可靠：一项横断面研究

International Journal of Social Determinants of Health and Health Services

IF0

2025-03-170

PRE

The potential impact of the Comprehensive and Progressive Agreement for Prans-Pacific Partnership on Thailand's hepatitis C treatment program

GLOBALIZATION AND HEALTH

IF4.5

2024-06-130

OAAI

Profits First, Health Second: The Pharmaceutical Industry and the Global South Comment on More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry's Role in Widening the Access Gap

INTERNATIONAL JOURNAL OF HEALTH POLICY AND MANAGEMENT

IF5.1

2024-05-180

OAAI

Direct-to-consumer advertising: a modifiable driver of overdiagnosis and overtreatment

BMJ EVIDENCE-BASED MEDICINE

IF7.6

2024-05-151

PRE

Phase IV Drug Trials With a Canadian Site: A Comparison of Industry-Funded and Non-Industry-Funded Trials

INTERNATIONAL JOURNAL OF HEALTH POLICY AND MANAGEMENT

IF5.1

2024-03-130

OAAI

Raising the bar for disclosure of industry payments to doctors

BMJ-BRITISH MEDICAL JOURNAL

IF42.7

2024-02-290

PRE

Therapeutic Value of Orphan Drugs Approved by Health Canada: A Cross-Sectional Study

JOURNAL OF GENERAL INTERNAL MEDICINE

IF4.2

2024-02-070

PRE

Quality and quantity of data used by Health Canada in approving new drugs

FRONTIERS IN MEDICINE

IF3

2023-11-303

OAAI

Prevalence and nature of manufacturer-sponsored patient support programs for prescription drugs in Canada: a cross-sectional study

CANADIAN MEDICAL ASSOCIATION JOURNAL

IF11.3

2023-11-261

OAAI

Therapeutic value of new medicines not submitted to Health Canada 2014-2021: Cross-sectional study

HEALTH POLICY

IF3.4

2023-10-013

PRE

Medicine donations: a review of policies and practices

GLOBALIZATION AND HEALTH

IF4.5

2023-09-013

OAAI

Joel Lexchin

个人简介

教育背景

工作经历

荣誉奖项

研究方向